Brigatinib/Brigatinib usage and dosage

Brigatinib is primarily indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) confirmed by a U.S. Food and Drug Administration (FDA)-certified test.

The recommended dose of brigatinib is: 90 mg orally once daily for the first 7 days, then increasing the dose to 180 mg orally once daily, until disease progression or unacceptable toxicity. Brigatinib can be taken with or without food. Patients should swallow the tablet whole and do not crush or chew the tablet. If you miss a dose of brigatinib or develop vomiting after taking a dose, do not take another dose and take the next dose at the scheduled time.

If the patient experiences adverse reactions while taking brigatinib, the doctor may adjust the drug dose. When the dose is 90 mg, the first dose can be adjusted to 60 mg once a day. Patients who cannot tolerate it will stop using it; when the dose is 180 mg, the first dose can be adjusted to 120 mg once a day, the second dose can be adjusted to 90 mg once a day, and the third dose can be adjusted to 60 mg once a day. Once the dose is reduced due to adverse effects, do not subsequently increase the brigatinib dose. If a patient is taking brigatinib for 14 days or more without interruption due to adverse effects, continue treatment at a dose of 90 mg once daily for 7 days before increasing to the previously tolerated dose.

During the medication period, you should avoid co-administration with other drugs, which may lead to interactions; for example, avoid concurrent use with strong or moderate CYP3A inhibitors; the dose of brigatinib needs to be reduced if necessary; such as avoid concurrent use with moderate CYP3A inducers; if necessary, the dose of brigatinib needs to be increased. For patients with severe hepatic and renal impairment, the dose of brigatinib needs to be reduced by approximately 40%.